Please upgrade your browser.
Mediaplanet Publishing released a Kidney Health report to targeted markets in USA Today. The report is distributed to 1 million readers with contributions from Kidney Cancer Association, National Kidney Foundation, Fresenius Medical Care North America, UKidney, Medical Education Institute, and National Kidney Registry.
Active surveillance may be a viable short-term treatment option in select patients with small renal masses, researchers from Fox Chase Cancer Center, Philadelphia.
Learn about state-of-the art treatment of kidney cancer from world-renown experts.
Independent Sector urges Congress to reject proposals to limit the value of itemized deductions for charitable donations. As nonprofit organizations struggle to meet increased demand for services and raise the necessary funds to meet those needs, Congress should seek to encourage all individuals, regardless of income and wealth, to give more to charitable organizations.
High Cost-Sharing and Higher Concurrent Prescription Activity Are Key Factors Related to Abandonment of Medicines
Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq:ONXX - News) today announced that data evaluating the use of Nexavar® (sorafenib) tablets will be presented in a scientific forum at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7, in Chicago.
Company expected to seek U.S. approval this year
Now, researchers at Fox Chase Cancer Center have discovered that the lymphocyte count--which is routinely measured in laboratory tests--is a simple and effective prognostic indicator in patients with renal cell carcinoma (RCC).
Should people at risk for kidney cancer take red yeast rice, the dietary supplement? A study links Agent Orange with renal cancer.
The outcome of patients with metastatic renal cell carcinoma has been substantially improved with administration of the currently available molecularly targeted therapies. However, proper selection of therapy and management of toxicities remain challenging.
|Powered by NeonCRM|